Desmopressin Nasal Spray 5 ml

Product Overview

Desmopressin Nasal Spray 5 ml is a prescription medication supplied by United Biotech for managing excessive thirst and urination. The sterile intranasal formulation delivers a precise 5 ml volume per bottle and is indicated for nocturnal enuresis (bed‑wetting) and central diabetes insipidus. Administered via the nasal mucosa, the spray provides rapid absorption and an alternative to oral tablets or injections. United Biotech manufactures the product under Good Manufacturing Practice (GMP) standards, ensuring consistent potency and safety for each batch.

What is Desmopressin Nasal Spray

Desmopressin is a synthetic analog of antidiuretic hormone vasopressin. It binds selectively to V2 receptors in the kidney’s collecting ducts, promoting water reabsorption and reducing urine output. The nasal spray delivers the drug directly into the bloodstream through the richly vascularized nasal mucosa, offering faster onset than oral tablets. Each actuation releases a calibrated dose, allowing clinicians to achieve steady plasma levels with minimal fluctuations. This route is especially useful for patients who need quick control of polyuria or who have difficulty swallowing pills.

Uses and Benefits

The spray is primarily used to reduce nighttime urine volume in children aged six years and older, helping families achieve uninterrupted sleep, and to treat central diabetes insipidus across all ages by restoring the hormone’s ability to concentrate urine. By decreasing polyuria, it lowers the risk of skin irritation and dehydration. Off‑label use in attention‑deficit/hyperactivity disorder‑related enuresis has been studied, but clinicians should restrict use to approved indications unless a specialist advises otherwise. The once‑or‑twice‑daily dosing schedule promotes adherence and supports long‑term disease management.

How It Works

Desmopressin acts as a selective agonist at V2 receptors located on the basolateral membrane of principal cells in the renal collecting duct. Activation of these receptors triggers insertion of aquaporin‑2 water channels into the apical membrane, enhancing water reabsorption without sodium movement. This mechanism reduces free water clearance, leading to decreased urine volume and thirst. Because the nasal spray enters systemic circulation within minutes, therapeutic levels are reached rapidly, providing swift clinical effect. Controlled release from the spray maintains stable plasma concentrations, minimizing peaks that could cause hyponatremia while sustaining efficacy throughout the dosing interval.

Dosage Guidelines

Treatment is individualized based on age, weight, and indication. For nocturnal enuresis, a single actuation (equivalent to 0.5 mg desmopressin) is typically taken about 60 minutes before bedtime, not exceeding one dose per night. In central diabetes insipidus, initial dosing often ranges from 0.1 mg to 0.2 mg administered two to three times daily, with adjustments guided by serum sodium and urine concentration. Patients should prime the spray before first use, avoid blowing into the nozzle, and store the bottle at room temperature away from heat. If a dose is missed, do not double up; simply continue with the next scheduled actuation to maintain consistent plasma levels.

Side Effects

Most adverse events are mild and transient, including headache, nasal congestion, epistaxis and mild abdominal discomfort. Less common but clinically important effects comprise hyponatremia, visual disturbances and abdominal cramps, which require regular laboratory monitoring, especially in children and patients with renal impairment. Rare allergic reactions such as rash or urticaria necessitate immediate discontinuation and medical evaluation. Patients should report persistent or worsening symptoms to their healthcare provider, as dose modification may be needed to balance therapeutic benefit with safety.

Warnings and Precautions

Prior to therapy, a comprehensive medical history should be reviewed for conditions that increase risk, such as hyponatremia, severe renal disease or uncontrolled hypertension. Concomitant use of other antidiuretic agents, NSAIDs or selective serotonin reuptake inhibitors may potentiate the antidiuretic effect and require dose adjustment. Pregnant or lactating women should only use the spray under physician guidance, weighing potential benefits against fetal or neonatal risks. Keep the medication out of children’s reach, as accidental ingestion of multiple actuations can cause severe water intoxication. Regular follow‑up visits are recommended to assess response, monitor electrolytes and adjust dosing as needed.

Frequently Asked Questions

Q: What condition does Desmopressin Nasal Spray treat?
A: Desmopressin Nasal Spray is indicated for two primary medical conditions. First, it reduces nighttime urine production in children aged six years and older who experience bed‑wetting, helping families achieve uninterrupted sleep. Second, it treats central diabetes insipidus in patients of any age by supplementing the deficient antidiuretic hormone, thereby decreasing excessive thirst and urination. The United States National Institutes of Health (NIH) recognizes these uses in its clinical guidelines for pediatric urology and endocrine disorders.

Q: How quickly does the spray work?
A: The onset of diuretic effect after a single actuation of Desmopressin Nasal Spray typically appears within 30 to 60 minutes, making it suitable for patients who require rapid control of polyuria. This rapid absorption is attributed to the rich vascular supply of the nasal mucosa, which allows the active molecule to enter the bloodstream swiftly. Clinical studies cited by the U.S. Food and Drug Administration (FDA) demonstrate consistent plasma concentrations within this time frame, supporting its use before bedtime for nocturnal enuresis or as needed for acute symptoms of diabetes insipidus.

Q: Can the spray be used in adults?
A: Yes, adults may use Desmopressin Nasal Spray under medical supervision for both nocturnal enuresis and central diabetes insipidus. In adult patients, the dosing regimen is often lower than that used in children and is titrated based on serum sodium and urine output. The medication is listed on the MedlinePlus database as an approved therapy for diabetes insipidus, confirming its safety profile when prescribed appropriately. Physicians consider age, renal function, and concomitant medications before initiating treatment to minimize the risk of adverse events such as hyponatremia.

Q: What should I do if I miss a dose?
A: If a dose of Desmopressin Nasal Spray is inadvertently missed, the recommended approach is to skip the missed actuation and resume the regular dosing schedule at the next planned time. Taking a double dose to compensate is not advised, as it can increase the likelihood of water retention and electrolyte imbalance. Patients should be instructed to maintain a consistent dosing routine and to keep the spray in a visible location as a reminder. If dosing errors occur frequently, a discussion with a healthcare professional is recommended to adjust the regimen.

Q: Are there any dietary restrictions?
A: There are no specific dietary restrictions associated with Desmopressin Nasal Spray; however, patients are advised to follow fluid‑intake recommendations provided by their clinician, especially when managing diabetes insipidus. Maintaining adequate hydration while avoiding excessive fluid consumption helps prevent both dehydration and overhydration. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH, offers guidance on fluid management strategies for individuals using antidiuretic agents. Always discuss any changes in diet or fluid habits with a qualified medical professional.

Related Products

• D-Pressin Nasal Spray 5ml (Desmopressin)
• Desmopressin 120mcg (Generic)
• Desmopressin 0.2mg (Generic)
• Desmopressin 0.1mg (Generic)
• Desmopressin 60mcg (Generic)
• Minirin 0.1mg (Desmopressin)
• Minirin (Desmopressin)
• Minirin 0.2mg (Desmopressin)
• Minirin Nasal Spray (Desmopressin)
• Minirin Melt 120 mcg (Desmopressin)
• Minirin Melt 60mcg (Desmopressin)